PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of neurologyNeurologyAmerican Academy of Neurology
 
Neurology. 2013 February 19; 80(8): 712–718.
PMCID: PMC3589297

Microvascular brain pathology and late-life motor impairment

Aron S. Buchman, MD,corresponding author

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. (1) NIH R01AG17917, co-I, 2001-13; (2) NIH R01AG24480, PI, 2005-12, R01AG043379 (PI), 2012-2017, R01NS078009 (PI), 2012-2017

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Lei Yu, PhD,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NIH R01AG033678 [co-investigator], NIH R01AG024871 [co-investigator], NIH R01AG024871 [co-investigator], NIH P30AG010161 [co-investigator], NIH R01AG015819 [co-investigator], NIH R01HL096944 [co-investigator], NIH R01AG036042 [co-investigator], NIH R01AG038651 [co-investigator], NIH R01AG040039 [co-investigator], NIH R01AG034374 [co-investigator], NIH U01AG032984 [co-investigator]

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Patricia A. Boyle, PhD,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NIH/NIA R01AG034374, PI, 2009-2014NIH/NIA R01AF034119, Co-I, NIH/NIA R01AG033678, PI, 2009-2014

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Steven R. Levine, MD,

Scientific Advisory Boards:

  1. (1) Independent Medical/Safety Monitor for NINDS-funded IMS 3, FAST MAG, INSTINCT, and CLEAR-ER(2) Adjudication committee for NINDS-funded WARCEF

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. (1) Genentech-sponsored investigator meeting - travel expenses reimbursement in 2010, 2011

Editorial Boards:

  1. (1) MEDLINK, Associate Editor, 1996-present(2) National Stroke Association, scientific content advisor, 2010, 2011

Patents:

  1. NONE

Publishing Royalties:

  1. (1) Book: Transient Ischemic Attacks, Blackwell Futura, 2004

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. (1) Genentech-sponsored investigator meeting - consultant, 2010(2) Genentech study on cost-effectiveness of primary stroke centers, 2011 - consultant within a study group

Speakers' Bureaus:

  1. (1)Medical Education Speakers Network, lecturer, 2008-2012(2)NCME, lecturer, 2008-2011

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. (1)NIH-NHLBI 1R01 HL096944, principal investigator, 2009-2013(2) NIH-NINDS 1UO1 NS044364, Independent safety monitor, 2003 - 2012(3) NIH-NINDS 1 U10 NS077378,PI, 2011 - 2017(4) NIH-NINDS 1 U10 NS080377, PI, 2012 - 2017(5) NIH-NINDS 1 R25 NS079211, MPI, 2012- 2017(6) The Patient-Centered Outcomes Research Institute (PCORI) 1IP2PI000781, scientific PI, 2012-2014(7) NIH-NIA 1 R01 AG040039, Co-I, 2011-2016(8) NIH-NINDS 2 P50 NS044283, safety monitor, 2008-2013(9) NIH-NINDS 2 U01 NS052220, independent medical monitor, 2005-2013

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Sukriti Nag, MD, PhD,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. The blood-brain & Other neural barriers, Springer Science+ Business Media,Humana Press, 2011Nag S (Editor)

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Julie A. Schneider, MD,

Scientific Advisory Boards:

  1. 1. served on scientific advisory board for GE Healthcare(2010)2. served on scientific advisory board for Eli Lilly andCompany (2011)

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. 2005-current Journal Histochemistry and Cytochemistry (Monitoring editor)2008-current International Journal of Clinical andExperimental Pathology (IJCEP, ISSN 1936-2625) (Editorial Board)2010 Journal of Alzheimer's Disease (Associate Editor)

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. Neuropathology consultant, AVID radiopharmaceuticals 2009-12

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. AVID radiopharmaceutical phase III clinical trialNeuropathologist 2010-2011

Research Support, Government Entities:

  1. 1R01AG042210 (Schneider)07/1/12- 06/30/17Epidemiologic Study of TDP-43 Pathology in Aging andDementia Major goal is to determine whether age-related TDP-43pathology represents a separate pathologic processassociated with a dementia syndrome with a distinctcognitive phenotype and specific genetic risk factors thatare separate from AD.Role: Principal investigator
    R01NS078009 (Buchman) 9/15/12-6/30/17 NINDS The Clinical Profile of Parkinson's Disease (PD)Pathology. The overall goal is to characterize the clinical profileof PD pathology in older persons without a diagnosis of PD.Role: co-investigator
    R01AG043379 (Buchman) 9/30/12-8/31/17 NIA Brain and Spinal Cord Microvascular Pathology in Late-LifeMotor ImpairmentThe overall goal is to test the hypothesis that specificmicrovascular pathologies in the brain and spinal cordcontribute to late-life motor impairment.
    U01AG016976 (Kukull/Montine) 7/1/12-6/30/13 NIA (Pilot) Optimization of Neuropathologic Assessment ofAlzheimer's Disease; The overall goal is to optimizeneuropathologic diagnosis of Alzheimer's disease foruniformity and accurancy across centersRole: Site Principal Investigator
    P30 AG10161 (Bennett)9/30/91-6/30/16Rush Alzheimer's Disease Core CenterMajor goals to provide core infrastructure support forresearch regarding aging/dementia/AD. Role: Associate Director, Core Leader: Neuropathology Core
    R01 AG031553 (Morris)3/15/08 - 2/28/13Epidemiologic Study of Brain Vitamin E, Diet, andAge-Related Neurologic Diseases; Major goal is analyzeVitamin E in brain, CSF, serum, and diet and compare toneuropathology and dementia. Role: Co-Principal Investigator
    R01 AG17917 (Bennett)9/30/01-6/30/13Epidemiologic Study of Neural Reserve and Neurobiology ofAging; Major goals are to identify structural bases of reserveand examine mechanisms risk factors lead to age-relatedfunctional impairment.Role: Co-Investigator
    R01 AG15819 (7/1/98 - 6/30/13Risk Factors, Pathology and Clinical Expressions of ADThe major goals of this project are to examine thepathologic mechanisms through which risk factors lead toclinical AD. Role: Co-investigator
    P01 AG14449 (Mufson)9/1/97 - 3/31/13 Neurobiology of Mild cognitive impairment in the Elderly;The major goals are to identify neurobiologic substratesof mild cognitive impairment. Role: Co-investigator (Neuropathologist)
    R01AG033678-01 (Boyle)9/15/2009 - 6/30/14Epidemiologic study of impaired decision making inpreclinical Alzheimer's disease.The overall goal of the proposed epidemiologic study is toexamine the causes and consequences of impaireddecision-making in old age.Role: Neuropathologist
    R01AG034374 (Boyle)8/15/2009 -7/31/14Characterizing the behavior profile of healthy cognitiveaging.Goal is to use innovative statistical approaches tocharacterize the profile of healthy cognitive agingdefined as age-related cognitive change not accounted forby the presence of common neuropathologies (i.e.,Alzheimer's disease, cerebral infarcts, and the Lewy bodydiseases) or terminal decline.Role: Neuropathologist.
    P01 AG09466 (deToledo-Morrell) 4/1/1991-8/31/12 Anatomic, Physiologic, Cognitive Pathology of AD; majorgoals- to identify neurobiologic, radiologic, physiologic,cognitive markers with AD; Role: Co-Investigator; Neuropathologist, Administrative Core
    R01 AG36042 (Bennett)9/15/09-8/31/14Exploring the Role of the Brain Epigenome: CognitiveDecline and Life ExperiencesThe goal of the study is to examine the relation of DNAmethylation to cognitive decline and life experiences.Role: Neuropathologist
    R01 HL096944 (Levine)9/1/09 - 6/30/13Stroke and aPL: Community-Based Clinicopathologic StudyThe major goal of this project is to investigate the roleand mechanisms of antiphospholipid antibodies (aPL) in thedevelopment of pathologically-proven ischemic braininfarction.Role: Neuropathologist
    R01AG040039 (Arvanitakis)9/30/11-8/31/16 NationalInstitute on AgingVascular Cognitive and Motor Decline: Impact of aPLThe major goal of this project is to investigate the roleand mechanisms of antiphospholipid antibodies (aPL) in thedevelopment of cognitive and motor decline in aging.
    R01AG039478 (Arnold)4/1/11-3/31/16 NationalInstitute on AgingTargeted Proteomics of Resilient Cognition in AgingThe major goal of the study is to identify candidateproteins and pathways that best confer cognitiveresilience despite the accumulation of neurodegenerativedisease pathology.Role: Neuropathologist
    R01AG036836 (DeJager)9/15/11-8/31/15 National Institute on AgingExploring the Role of the Brain Transcriptome in CognitiveDeclineThe major goal is to investigate the transcriptome ofhuman brain tissue to identify molecular pathways thatcontribute to cognitive decline. Role: Neuropathologist

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
and David A. Bennett, MD

Scientific Advisory Boards:

  1. (1) Vigorous Minds, Scientific Advisory Board

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. Danone, paid for travel to scientific meeting

Editorial Boards:

  1. (1) Neurology, Editorial Board;(2) Current Alzheimer Research, Editorial Board;(3) Neuroepidemiology, Editorial Board(4) Frontiers Neurology, Editorial Board

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. (1) Danone, Inc., (2) Wilmar Schwabe GmbH & Co., (3) Eli Lilly, Inc., (4) the Gerson Lehrman Group

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. (1) Danone Inc., PI

Research Support, Government Entities:

  1. NIH: P30AG10161, PI; R01AG15819, PI; R01AG17917, PI; R01AG36042, PI; U01AG32984, Co-I; R01AG22018, Co-I; R01AG33678, Co-I; R01AG36836, Co-I; R01AG41797, Co-I; R01AG42210, Co-I; and Illinois Department Public Health

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Abstract

Objective:

To test the hypothesis that microvascular brain pathology is associated with late-life motor impairment.

Methods:

More than 2,500 persons participating in the Religious Orders Study or the Memory and Aging Project agreed to annual motor assessment and autopsy. Brains from 850 deceased participants were assessed for microvascular pathology including microinfarcts, cerebral amyloid angiopathy, and arteriolosclerosis, and we examined their association with global motor scores proximate to death.

Results:

Mean age at death was 88.5 years. More than 60% of cases had evidence of 1 or more microvascular pathologies and of these more than half did not have observed macroinfarcts. In separate regression models adjusted for age, sex, and education, microinfarcts and arteriolosclerosis were associated with level of motor function proximate to death (arteriolosclerosis, estimate, −0.027, SE 0.005, p < 0.001; microinfarcts, estimate, −0.017, SE 0.008, p = 0.026). These associations were not attenuated when controlling for vascular risk factors and diseases, postmortem interval, or interval from last clinical examination, and did not vary with level of cognition or presence of dementia proximate to death. When the 3 microvascular pathologies, macroinfarcts, and atherosclerosis were considered together in a single model, more severe arteriolosclerosis (estimate, −0.021, SE 0.005, p < 0.001) and macroinfarcts (estimate, −0.019, SE 0.006, p < 0.001) showed separate effects with the level of motor function proximate to death.

Conclusions:

Microvascular brain pathology is common in older adults and may represent an under-recognized, independent cause of late-life motor impairment.

As our population ages, the increasing burden of chronic motor impairments and disability is a growing public health challenge. Impaired motor function is a common consequence of aging and is present in 50% of adults by age 85 years.1 Importantly, these impairments are progressive and associated with adverse health outcomes including mortality, falls, disability, and dementia,2 but the pathologic basis for these impairments is unclear. Vascular disease is common with increasing age. Converging evidence suggests that small-vessel disease may be a systemic age-related disorder which affects many organs including heart, kidney, and retina.36 Similarly, even in the absence of stroke, brain imaging of older adults shows that lacunar infarcts as well as nonspecific white matter hyperintensities commonly thought of as surrogates for microvascular brain pathology are common in old age and associated with impaired cognition, gait, balance, falls, motor speed, and disability.712 While conventional brain imaging is an excellent tool for identifying many types of vascular pathologies, it cannot identify specific small-vessel diseases and the extent to which these pathologies are related to late-life motor impairments.7,1315 To address these gaps in the literature, we used clinical and postmortem data from the first 850 decedents in the Religious Orders Study (ROS) and the Memory and Aging Project (MAP), clinical-pathologic cohort studies of chronic conditions of aging.16,17 We tested the hypothesis that microvascular brain pathology, including microinfarcts, cerebral amyloid angiopathy (CAA), and arteriolosclerosis, are associated with motor function proximate to death while controlling for macroinfarcts and atherosclerosis.

METHODS

Subjects.

Participants are from 2 ongoing studies of aging which employ common antemortem and postmortem data collection allowing analyses of data from the combined cohorts. At the time of these analyses, motor assessment proximate to death and completed postmortem data were available for 850 persons (ROS: 469; MAP: 381).16,17

Assessment of motor function.

A uniform structured clinical evaluation is performed each year that includes medical history, neurologic examination, and neuropsychological performance tests. Motor performances tested included grip and pinch strength, finger tapping, Purdue pegboard testing, gait (time and number of steps to walk 8 feet and turn 360°), and balance (time to stand on each leg and then on their toes for 10 seconds and the number of steps off line when walking an 8-foot line in a heel to toe manner).2 These measures were scaled and averaged to obtain a summary global motor score. Composite measures of manual strength (2 tests), manual dexterity (2 tests), and gait (4 tests) were formed in a similar manner. We did not form a composite balance measure because the balance tests, unlike the other motor tests, were sometimes not attempted.

Postmortem brain assessment.

The average postmortem interval was 8.40 hours (SD = 7.99 hours). Brains were removed, weighed, and brain regions that were not designated for freezing were immersion fixed in 4% paraformaldehyde for a minimum of 72 hours. A uniform gross and microscopic neuropathologic examination including postmortem indices of Alzheimer disease (AD) and Lewy body pathology was conducted as previously described.18

Microvascular pathology.

Microscopic cerebral infarcts.

In all cases, the following regions were dissected, processed, and embedded for review: middle frontal cortex, middle temporal cortex, anterior cingulate cortex, inferior parietal cortex, entorhinal cortex, hippocampus, anterior basal ganglia, anterior thalamus, and hemisection of midbrain including substantia nigra. Hematoxylin & eosin–stained 6-μm sections were used to identify microscopic infarcts. Microscopic infarcts were defined as any infarct seen only by microscopic examination. Microscopic infarcts ranged from cavitated to a focal area of shrinkage due to astrogliosis associated with few remaining macrophages. Any chronic microinfarct visualized microscopically by the neuropathologist was included in our analyses. Cases that were ambiguous were reviewed by a second neuropathologist and a consensus was employed. Each microscopic infarct was recorded for age and location.19

Cerebral amyloid angiopathy.

CAA pathology was assessed in 5 brain regions, including midfrontal, inferior temporal, angular gyrus, and calcarine cortices, and the hippocampus. Two or more blocks from each region were dissected from 1-cm-thick paraformaldehyde-fixed slabs, then paraffin-embedded, cut into 20-μm sections, and mounted on glass slides. The presence of CAA was assessed in each region using immunohistochemical labeling with monoclonal antihuman-amyloid-β 1-16 (1:300, Elan Pharmaceuticals, San Francisco, CA). Positive controls were included in each run. CAA pathology was measured in 5 brain regions using a 5-point scale (0–4) as previously described.20

Cerebral arteriolosclerosis.

Arteriolosclerosis describes the histologic changes commonly found in the deep penetrating small vessels of the brain in aging, including intimal deterioration, smooth muscle degeneration, and fibrohyalinotic thickening of arterioles, with consequent narrowing of the vascular lumen. There are no standard guidelines to grade severity of arteriolosclerosis. We evaluated the vessels of the anterior basal ganglia with a semiquantitative grading system from 0 (none) to 4 (severe) indicating more than twice the normal wall thickness as previously described.21

Other cerebrovascular pathologies.

Macroscopic cerebral infarcts.

We reviewed 1-cm slabs and recorded the age, volume (in mm3), side, and location of all cerebral infarcts visible to the naked eye as previously reported.18 Hemorrhagic infarcts were included in analyses. There was no minimum size required for macroscopic infarcts. All grossly visualized and suspected macroscopic infarcts were microscopically reviewed for histologic confirmation. Infarct age (acute, subacute, and chronic) was estimated by gross histologic features and degree of cavitation.

Cerebral atherosclerosis.

This describes the segmental or circumferential subintimal accumulation of lipid, plasma proteins, and calcium deposition (plaque) in the walls of large arteries. It was assessed on gross examination of the anterior, middle, and posterior cerebral arteries and their proximal branches at the circle of Willis using a semiquantitative scale of none (0) to severe (5) indicating near total or total involvement of all visualized arteries.

Statistical analysis.

The associations among the microvascular pathologies were examined with Spearman correlations. In primary analyses, we used the total number of infarcts for each case. We created additional variables for secondary analyses. For quantity, we created a predictor with 3 levels: no (reference level), one, and multiple macroscopic infarcts, as previously described.18 For location, we created 2 variables: cortical (presence of any microscopic infarcts in any cortical region; reference = no cortical microscopic infarcts) and subcortical microscopic infarcts (presence of any microscopic infarcts in any subcortical region; reference = no subcortical microscopic infarcts). To investigate quantity and location simultaneously, we created 4 variables: one and multiple cortical microscopic infarcts (compared to persons with no cortical macroscopic infarcts), and one and multiple subcortical microscopic infarcts (compared to no subcortical microscopic infarcts). Since the interval between last clinical examination and death in this group was on average 8.90 months (SD = 10.31), and perimortem infarcts (acute and subacute) were not related to global motor scores recorded 9 months earlier (results not shown), only the total of chronic infarcts (estimated at being over 3–6 months in age) were included in the primary analyses. We used a series of regression models to document the association of postmortem indices of microvascular pathology with global motor score proximate to death. All analyses controlled for age, sex, and education. We then added additional terms for vascular risk factors and diseases to examine their influence on these associations. Next, we added an interaction term to examine whether the association of microvascular pathologies and global motor score varied with cognitive status or between the 2 cohorts. Model assumptions of linearity, normality, independence of errors, and homoscedasticity of errors were examined graphically and analytically and were adequately met. All analyses were carried out using SAS/STAT software version 9 (SAS Institute Inc., Cary, NC) on a Hewlett Packard ProLiant ML350 server running LINUX.22

Standard protocol approvals, registrations, and patient consents.

The study was approved by the institutional review board of Rush University Medical Center. Written informed consent and an anatomical gift act for brain donation at the time of death was obtained from all study participants.

RESULTS

Summary of global motor score and cerebrovascular pathologies.

Scores on the global motor score ranged from 0.24 to 1.41 (mean = 0.61; SD = 0.22) with higher scores indicating better motor performance. The clinical characteristics of cases included at their last visit before death and postmortem indices are included in table 1.

Table 1
Characteristics of participants at last visit proximate to death (n = 850)

More than 60% (n = 508, 61.2%) of cases showed evidence of one or more indices of microinfarcts or moderate to severe microvascular pathology (1 measure n = 329, 39.6%; 2 measures n = 149, 18.0%; and all 3 measures n = 30, 3.6%). In more than 50% of the cases with microvascular pathology, macroinfarcts were not observed (n = 282, 55.5%). Additional details on the frequency and the severity of vascular pathologies are included in table 1.

Microscopic infarcts were modestly associated with arteriolosclerosis (r = 0.12, p < 0.001) but showed only a trend with CAA (r = 0.06, p = 0.08) and arteriolosclerosis was modestly associated with CAA (r = 0.09, p = 0.01).

Association of microvascular pathology and global motor score.

We conducted a series of linear regression models to examine the relation of microvascular pathologies with global motor scores prior to death controlling for age at time of death, sex, and education. The total number of microinfarcts was associated with the level of global motor score proximate to death (table 2, model A). The figure contrasts the level of global motor scores in individuals with and without microinfarcts. In further analyses multiple microinfarcts (estimate, −0.055, SE 0.023, p = 0.016) rather than single microinfarcts were related to global motor score. There was a marginal association for subcortical microinfarcts and global motor score (estimate, −0.034, SE 0.019, p = 0.066) but not cortical microinfarcts (results not shown).

Figure
Microvascular pathology and motor function proximate to death
Table 2
Microvascular pathology is related to global motor score proximate to deatha

The severity of arteriolosclerosis was strongly related to the level of global motor score proximate to death (table 2, model B). In contrast, CAA was not associated with the level of motor function proximate to death (table 2, model C). The figure contrasts global motor scores in individuals with moderate to severe arteriolosclerosis vs none or mild arteriolosclerosis.

Next, we included all 3 microvascular pathologies in a single model which controlled for demographics, macroinfarcts, and atherosclerosis. We used the adjusted R2 to convey the magnitude of the association for the addition of postmortem indices to the core model with demographic variables alone. Together these vascular pathologies accounted for 4% of the R2 of global motor score after considering demographic variables. Both arteriolosclerosis and macroinfarcts showed separate effects with the level of motor function proximate to death (table 2, model D). AD and Lewy body pathology have been reported to be associated with level of motor function in older adults.23 In a final model, we added terms to model D to control for AD and Lewy body pathologies and the associations of arteriolosclerosis and macroinfarcts with global motor score were unchanged (results not shown).

The associations between microinfarcts and arteriolosclerosis and global motor score were not attenuated after controlling for vascular risk factors and diseases, postmortem interval, or interval from last clinical examination (results not shown). In further analyses, we added interaction terms to our core models, to examine if there was an interaction between microvascular pathology and the presence of dementia or the level of cognitive function proximate to death. The interaction terms were not significant (results not shown), suggesting that the association of microvascular pathology and global motor score did not vary in cases with and without dementia or with the level of cognition proximate to death. In a final set of analyses we examined whether the association of microvascular pathology with global motor scores varied by cohort (MAP or ROS). There was not a significant interaction between cohorts and microinfarcts (estimate, 0.017; SE 0.015, p = 0.244) or arteriolosclerosis (estimate, 0.002; SE 0.011, p = 0.895), suggesting that the association between microvascular pathology and global motor scores was similar in both cohorts.

Associations of microvascular pathology with the components of global motor score.

To see if microvascular pathology was more strongly associated with different components of the global motor score, we repeated the original analyses with several components of global motor score. In separate regression models, microinfarcts were associated with manual dexterity and gait, arteriolosclerosis was strongly associated with all the motor components, and CAA was not associated with these motor measures (table 3).

Table 3
Microvascular pathology and components of global motor scorea

DISCUSSION

In this clinical–autopsy study of 850 community-dwelling older persons, microvascular pathology including microinfarcts, CAA, and arteriolosclerosis was common and observed in more than 60% of cases. Moreover, up to 35% had microvascular pathology alone without evidence of macroinfarcts. Not only were these pathologies common, but microinfarcts and arteriolosclerosis were associated with the severity of motor function proximate to death. When considered together in a single model, arteriolosclerosis and macroinfarcts showed independent effects with the level of global motor score proximate to death even when controlling for the other microvascular pathologies and atherosclerosis. Thus, many older adults have microvascular brain pathology that might not be detected prior to death. As a consequence, cerebrovascular disease may be an even larger public health challenge than currently estimated and the accumulation of microvascular pathology in the brains of older adults may represent an under-recognized cause of late-life motor impairments.

Impaired motor function in older adults is common, progressive, and associated with adverse health outcomes.1,2 A variety of non-neurologic diseases such as chronic pulmonary or heart disease as well as neurologic conditions including Parkinson disease, amyotrophic lateral sclerosis, and cerebrovascular disease are well known to affect motor function. In contrast, motor deficits observed in older persons in the absence of overt diseases have been subsumed under several terms including sarcopenia,24 physical frailty,25 and parkinsonian signs.1 While these motor deficits are widely known to be related to adverse health outcomes, their underlying mechanisms are unclear. For example, recent work has shown that declining strength in older adults is not accounted for by loss of skeletal muscle bulk alone.26 On the other hand, others have reported both physiologic deficits in fully activating muscle as well as the accumulation of common neuropathologies in crucial motor-related brain regions of older adults without overt neurologic diseases, suggesting that neural factors may contribute to the development of late-life motor impairments.23,27,28 Brain imaging studies have also linked nonspecific white matter hyperintensities commonly thought of as surrogates for small vessel disease, with impaired gait, balance, falls, motor speed, and disability.712 Thus, like other organs, the accumulation of microvascular brain pathology may also contribute to late-life motor impairments in the absence of overt diseases.36 While extant brain imaging techniques may be very sensitive to the presence of white matter hyperintensities, complementary histopathologic studies are necessary to identify the specific types of small-vessel diseases affecting the brain.7,1315

The current clinical–histopathologic study provides important new data which complements extant brain imaging studies in several important ways. First, this study found that that one or more of 3 common microvascular pathologies including microinfarcts, CAA, or arteriolosclerosis are observed in more than 60% of older adults and up to 35% without evidence of macroinfarcts. Second, the current study found that microvascular pathology, in particular arteriolosclerosis and microinfarcts, were associated with the severity of motor impairment proximate to death. Third, after controlling for the presence of macroinfarcts, arteriolosclerosis was associated with level of motor function proximate to death. Together these data provide further support for an expanded conception of the role of cerebrovascular disease in older adults not only causing devastating acute deficits from strokes, but a potentially larger role in late-life motor and cognitive impairments, as suggested by brain imaging studies.712 These findings underscore the importance of explicating the biology of small-vessel diseases in older adults as their treatment would provide a host of new targets for interventions to mitigate the growing burden of late-life motor impairment in our aging population.

While vascular pathologies examined in the current study were linked with motor function, the variance explained by the 5 postmortem indices which were examined accounted for only about 4% of global motor score as compared to 12% accounted for by demographic variables age, sex, and education. While this is a small effect size, it has important implications at the population level. While it is possible that more precise measures of pathology would improve the prediction, it is more likely that there are other pathologic processes which we did not measure in the current study which may make additional contributions to motor function such as brain imaging measures of white matter integrity, microbleeds, or measures of CNS inflammation. Moreover, motor function derives from integrated motor systems which are located in both the brain and in the spinal cord, as well as peripheral nerve and muscle. Thus, damage to brain or spinal cord or both can cause motor deficits. Thus, it is also possible that microvascular pathology may also affect motor networks which are located outside of the brain, such as in the spinal cord, and make independent contributions to late-life motor impairments. The current results add further support to the idea that the accumulation of common neuropathologies in older adults including vascular pathologies, synuclein, as well as AD pathology may contribute to the development of what is currently considered “normal” age-related motor and cognitive symptoms in persons without overt diseases. Further studies which examine the entire central motor pathway are needed to delineate the full contribution of accumulating neuropathologies to late-life motor impairments.

The study has strengths that lend confidence in the findings. All subjects were recruited from the community and underwent an annual detailed clinical evaluation and on average were examined about 9 months proximate to death. Annual follow-up and autopsy rates were very high. Uniform, structured clinical and postmortem procedures were followed. All postmortem evaluations were performed by experienced and trained examiners blinded to all clinical data. The study also had limitations in that the cohort was selected and inferences regarding causality must be drawn with caution from observational studies. Further, the study did employ brain imaging of white matter integrity or neuronal, glial, or inflammatory changes in the brain that might cause both loss of motor function and microvascular pathologies in old age.

Supplementary Material

Data Supplement:

ACKNOWLEDGMENT

The authors thank all the participants in the Rush Memory and Aging Project and Religious Order Study and the staff employed at the Rush Alzheimer's Disease Center, including Traci Colvin, RN, and Tracey Nowakowski, MS, for project coordination; Wenqing Fan, MS, and Donna Esbjornson, MS, for statistical programming; and John Gibbons, MS, for data management.

GLOSSARY

AD
Alzheimer disease
CAA
cerebral amyloid angiopathy
MAP
Memory and Aging Project
ROS
Religious Orders Study

AUTHOR CONTRIBUTIONS

Dr. Buchman had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. He was involved with obtaining funding for the study, study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. Dr. Yu provided statistical analyses and interpretation and critical revision of the manuscript for important intellectual content. Drs. Boyle, Levine, Nag, and Schneider were involved in study design, acquisition of data, and critically revised the manuscript for important intellectual content. Dr. Bennett was involved with obtaining funding, study concept and design, acquisition of data, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content.

STUDY FUNDING

Supported by the NIH grants R01AG17917, P30AG10161, AG31553, R01AG24480, HL096944, AG040039, Illinois Department of Public Health, and the Borwell Endowment Fund. The funding organizations had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.

DISCLOSURE

The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

REFERENCES

1. Louis ED, Bennett DA. Mild Parkinsonian signs: an overview of an emerging concept. Mov Disord 2007;22:1681–1688. [PubMed]
2. Buchman AS, Leurgans SE, Boyle PA, Schneider JA, Arnold SE, Bennett DA. Combinations of motor measures more strongly predict adverse health outcomes in old age: the rush memory and aging project, a community-based cohort study. BMC Med 2011;9:42. [PMC free article] [PubMed]
3. Khalilzada M, Dogan K, Ince C, Stam J. Sublingual microvascular changes in patients with cerebral small vessel disease. Stroke 2011;42:2071–2073. [PubMed]
4. Ikram MA, Vernooij MW, Hofman A, Niessen WJ, van der Lugt A, Breteler MMB. Kidney function is related to cerebral small vessel disease. Stroke 2008;39:55–61. [PubMed]
5. Kwa VIH, van der Sande JJ, Stam J, Tijmes N, Vrooland JL., Group* ftAVM. Retinal arterial changes correlate with cerebral small-vessel disease. Neurology 2002;59:1536–1540. [PubMed]
6. Cheung N, Mosley T, Islam A, et al. Retinal microvascular abnormalities and subclinical magnetic resonance imaging brain infarct: a prospective study. Brain 2010;133:1987–1993. [PMC free article] [PubMed]
7. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia. Stroke 2011;42:2672–2713. [PMC free article] [PubMed]
8. Zheng JJJ, Delbaere K, Close JCT, Sachdev PS, Lord SR. Impact of white matter lesions on physical functioning and fall risk in older people. Stroke 2011;42:2086–2090. [PubMed]
9. Hajjar I, Quach L, Yang F, et al. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood/clinical perspective. Circulation 2011;123:858–865. [PMC free article] [PubMed]
10. Murray ME, Senjem ML, Petersen RC, et al. Functional impact of white matter hyperintensities in cognitively normal elderly subjects. Arch Neurol 2010;67:1379–1385. [PMC free article] [PubMed]
11. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010;341:c3666. [PMC free article] [PubMed]
12. Baezner H, Blahak C, Poggesi A, et al. Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology 2008;70:935–942. [PubMed]
13. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689–701. [PubMed]
14. Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts: the invisible lesions. Lancet Neurol 2012;11:272–282. [PMC free article] [PubMed]
15. Gouw AA, Seewann A, van der Flier WM, et al. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011;82:126–135. [PubMed]
16. Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the Rush Memory and Aging Project. Curr Alzheimer Res 2012;9:646–663. [PMC free article] [PubMed]
17. Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the Religious Orders Study. Curr Alzheimer Res 2012;9:628–645. [PMC free article] [PubMed]
18. Schneider JA, Wilson RS, Cochran EJ, et al. Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology 2003;60:1082–1088. [PubMed]
19. Arvanitakis Z, Leurgans SE, Barnes LL, Bennett DA, Schneider JA. Microinfarct pathology, dementia, and cognitive systems. Stroke 2011;42:722–727. [PMC free article] [PubMed]
20. Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, Schneider JA. Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann Neurol 2011;69:320–327. [PMC free article] [PubMed]
21. Schneider JA, Bienias JL, Wilson RS, Berry-Kravis E, Evans DA, Bennett DA. The apolipoprotein E {epsilon}4 allele increases the odds of chronic cerebral infarction detected at autopsy in older persons. Stroke 2005;36:954–959. [PubMed]
22. SAS/STAT User's Guide, version 9.3 [computer program]. Cary, NC: SAS Institute Inc.; 2011.
23. Buchman AS, Shulman JM, Nag S, et al. Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol 2012;71:258–266. [PMC free article] [PubMed]
24. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998;147:755–763. [PubMed]
25. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146–M156. [PubMed]
26. Delmonico MJ, Harris TB, Visser M, et al. Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr 2009;90:1579–1585. [PubMed]
27. Buchman AS, Schneider JA, Leurgans S, Bennett DA. Physical frailty in older persons is associated with Alzheimer disease pathology. Neurology 2008;71:499–504. [PMC free article] [PubMed]
28. Harridge SDR, Kryger A, Stensgaard A. Knee extensor strength, activation, and size in very elderly people following strength training. Muscle Nerve 1999;22:831–839. [PubMed]

Articles from Neurology are provided here courtesy of American Academy of Neurology